The role of B lymphocytes in the progression from autoimmunity to autoimmune disease

Clinical Immunology

Volumn 146, Issue 1, 2013, Pages 34-45

  Salinas, Gabriela Franco ^a   Braza, Faouzi ^b,c   Brouard, Sophie ^b   Tak, Paul Peter ^a,d   Baeten, Dominique ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b HÔTEL DIEU   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antigen presentation; B lymphocytes; Class switch; Epitope spreading; Regulatory B cells; Somatic hypermutation

Indexed keywords

AUTOANTIGEN; EPITOPE; IMMUNOSUPPRESSIVE AGENT;

ALLOIMMUNITY; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; EFFECTOR CELL; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOMATIC HYPERMUTATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; GRAFT SURVIVAL; HUMANS; IMMUNE TOLERANCE; MODELS, IMMUNOLOGICAL; RECEPTORS, ANTIGEN, B-CELL;

EID: 84870372431     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.10.005     Document Type: Review

References (157)

1. Yurasov S., Wardemann H., Hammersen J., Tsuiji M., Meffre E., Pascual V., Nussenzweig M.C. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 2005, 201:703-711.
2. Litzenburger T., Bluthmann H., Morales P., Pham-Dinh D., Dautigny A., Wekerle H., Iglesias A. Development of myelin oligodendrocyte glycoprotein autoreactive transgenic B lymphocytes: receptor editing in vivo after encounter of a self-antigen distinct from myelin oligodendrocyte glycoprotein. J. Immunol. 2000, 165:5360-5366.
3. Litzenburger T., Fassler R., Bauer J., Lassmann H., Linington C., Wekerle H., Iglesias A. B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice. J. Exp. Med. 1998, 188:169-180.
4. Menard L., Saadoun D., Isnardi I., Ng Y.S., Meyers G., Massad C., Price C., Abraham C., Motaghedi R., Buckner J.H., Gregersen P.K., Meffre E. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J. Clin. Invest. 2011, 121:3635-3644.
5. Inaoki M., Sato S., Weintraub B.C., Goodnow C.C., Tedder T.F. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J. Exp. Med. 1997, 186:1923-1931.
6. Habib T., Funk A., Rieck M., Brahmandam A., Dai X., Panigrahi A.K., Luning Prak E.T., Meyer-Bahlburg A., Sanda S., Greenbaum C., Rawlings D.J., Buckner J.H. Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J. Immunol. 2012, 188:487-496.
7. Bettelli E., Pagany M., Weiner H.L., Linington C., Sobel R.A., Kuchroo V.K. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J. Exp. Med. 2003, 197:1073-1081.
8. Robles D.T., Eisenbarth G.S., Dailey N.J., Peterson L.B., Wicker L.S. Insulin autoantibodies are associated with islet inflammation but not always related to diabetes progression in NOD congenic mice. Diabetes 2003, 52:882-886.
9. Toplak N., Kveder T., Trampus-Bakija A., Subelj V., Cucnik S., Avcin T. Autoimmune response following annual influenza vaccination in 92 apparently healthy adults. Autoimmun. Rev. 2008, 8:134-138.
10. Karali Z., Basaranoglu S.T., Karali Y., Oral B., Kilic S.S. Autoimmunity and hepatitis A vaccine in children. J. Investig. Allergol. Clin. Immunol. 2011, 21:389-393.
11. Martinuc P.J., Avcin T., Bozic B., Kuhar M., Cucnik S., Zupancic M., Prosenc K., Kveder T., Rozman B. Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. Clin. Exp. Immunol. 2005, 142:377-380.
12. DeRycke L., Baeten D., Kruithof E., Van den Bosch F., Veys E.M., De K.F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum. 2005, 52:2192-2201.
13. Gulez N., Karaca N.E., Aksu G., Kutukculer N. Increased percentages of autoantibodies in immunoglobulin A-deficient children do not correlate with clinical manifestations. Autoimmunity 2009, 42:74-79.
14. LaGasse J.M., Brantley M.S., Leech N.J., Rowe R.E., Monks S., Palmer J.P., Nepom G.T., McCulloch D.K., Hagopian W.A. Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study. Diabetes Care 2002, 25:505-511.
15. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., Harley J.B. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 2003, 349:1526-1533.
16. Nielen M.M., van S.D., Reesink H.W., van de Stadt R.J., van der Horst-Bruinsma I.E., de Koning M.H., Habibuw M.R., Vandenbroucke J.P., Dijkmans B.A. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004, 50:380-386.
17. Rantapaa-Dahlqvist S., de Jong B.A., Berglin E., Hallmans G., Wadell G., Stenlund H., Sundin U., van Venrooij W.J. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003, 48:2741-2749.
18. Ursum J., Bos W.H., van de Stadt R.J., Dijkmans B.A., van S.D. Different properties of ACPA and IgM-RF derived from a large dataset: further evidence of two distinct autoantibody systems. Arthritis Res. Ther. 2009, 11:R75.
19. Lyons J.A., San M., Happ M.P., Cross A.H. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur. J. Immunol. 1999, 29:3432-3439.
20. Bettelli E., Baeten D., Jager A., Sobel R.A., Kuchroo V.K. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J. Clin. Invest. 2006, 116:2393-2402.
21. Krishnamoorthy G., Lassmann H., Wekerle H., Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J. Clin. Invest. 2006, 116:2385-2392.
22. Chan O.T., Hannum L.G., Haberman A.M., Madaio M.P., Shlomchik M.J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 1999, 189:1639-1648.
23. Wong F.S., Wen L., Tang M., Ramanathan M., Visintin I., Daugherty J., Hannum L.G., Janeway C.A., Shlomchik M.J. Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. Diabetes 2004, 53:2581-2587.
24. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985, 314:537-539.
25. Kakiuchi T., Chesnut R.W., Grey H.M. B cells as antigen-presenting cells: the requirement for B cell activation. J. Immunol. 1983, 131:109-114.
26. Rock K.L., Benacerraf B., Abbas A.K. Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J. Exp. Med. 1984, 160:1102-1113.
27. O'Neill S.K., Shlomchik M.J., Glant T.T., Cao Y., Doodes P.D., Finnegan A. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J. Immunol. 2005, 174:3781-3788.
28. Tchernev G., Orfanos C.E. Antigen mimicry, epitope spreading and the pathogenesis of pemphigus. Tissue Antigens 2006, 68:280-286.
29. Janeway C.A., Paul T., Walport M., Shlomchik M. Immunobiology: The Immune System in Health and Disease 2005, Garland Science Publishing.
30. Topfer F., Gordon T., McCluskey J. Intra- and intermolecular spreading of autoimmunity involving the nuclear self-antigens La (SS-B) and Ro (SS-A). Proc. Natl. Acad. Sci. U. S. A. 1995, 92:875-879.
31. Keech C.L., Gordon T.P., McCluskey J. The immune response to 52-kDa Ro and 60-kDa Ro is linked in experimental autoimmunity. J. Immunol. 1996, 157:3694-3699.
32. McRae B.L., Vanderlugt C.L., Dal Canto M.C., Miller S.D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 1995, 182:75-85.
33. Tisch R., Yang X.D., Singer S.M., Liblau R.S., Fugger L., McDevitt H.O. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993, 366:72-75.
34. Ziegler A.G., Hummel M., Schenker M., Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 1999, 48:460-468.
35. van der Woude D., Rantapaa-Dahlqvist S., Ioan-Facsinay A., Onnekink C., Schwarte C.M., Verpoort K.N., Drijfhout J.W., Huizinga T.W., Toes R.E., Pruijn G.J. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann. Rheum. Dis. 2010, 69:1554-1561.
36. van de Stadt L.A., van der Horst A.R., de Koning M.H., Bos W.H., Wolbink G.J., van de Stadt R.J., Pruijn G.J., Dijkmans B.A., van S.D., Hamann D. The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann. Rheum. Dis. 2011, 70:128-133.
37. Shlomchik M., Mascelli M., Shan H., Radic M.Z., Pisetsky D., Marshak-Rothstein A., Weigert M. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. J. Exp. Med. 1990, 171:265-292.
38. Shlomchik M.J., Marshak-Rothstein A., Wolfowicz C.B., Rothstein T.L., Weigert M.G. The role of clonal selection and somatic mutation in autoimmunity. Nature 1987, 328:805-811.
39. Owens G.P., Ritchie A.M., Burgoon M.P., Williamson R.A., Corboy J.R., Gilden D.H. Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J. Immunol. 2003, 171:2725-2733.
40. Colombo M., Dono M., Gazzola P., Roncella S., Valetto A., Chiorazzi N., Mancardi G.L., Ferrarini M. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J. Immunol. 2000, 164:2782-2789.
41. Qin Y., Duquette P., Zhang Y., Talbot P., Poole R., Antel J. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J. Clin. Invest. 1998, 102:1045-1050.
42. Itoh K., Patki V., Furie R.A., Chartash E.K., Jain R.I., Lane L., Asnis S.E., Chiorazzi N. Clonal expansion is a characteristic feature of the B-cell repertoire of patients with rheumatoid arthritis. Arthritis Res. 2000, 2:50-58.
43. Stott D.I., Hiepe F., Hummel M., Steinhauser G., Berek C. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome. J. Clin. Invest. 1998, 102:938-946.
44. Gellrich S., Rutz S., Borkowski A., Golembowski S., Gromnica-Ihle E., Sterry W., Jahn S. Analysis of V(H)-D-J(H) gene transcripts in B cells infiltrating the salivary glands and lymph node tissues of patients with Sjogren's syndrome. Arthritis Rheum. 1999, 42:240-247.
45. Eilat D., Hochberg M., Pumphrey J., Rudikoff S. Monoclonal antibodies to DNA and RNA from NZB/NZW F1 mice: antigenic specificities and NH2 terminal amino acid sequences. J. Immunol. 1984, 133:489-494.
46. Diamond B., Scharff M.D. Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:5841-5844.
47. Guo W., Smith D., Aviszus K., Detanico T., Heiser R.A., Wysocki L.J. Somatic hypermutation as a generator of antinuclear antibodies in a murine model of systemic autoimmunity. J. Exp. Med. 2010, 207:2225-2237.
48. Wellmann U., Letz M., Herrmann M., Angermuller S., Kalden J.R., Winkler T.H. The evolution of human anti-double-stranded DNA autoantibodies. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9258-9263.
49. Mietzner B., Tsuiji M., Scheid J., Velinzon K., Tiller T., Abraham K., Gonzalez J.B., Pascual V., Stichweh D., Wardemann H., Nussenzweig M.C. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:9727-9732.
50. Liu Y.J., Malisan F., de B.O., Guret C., Lebecque S., Banchereau J., Mills F.C., Max E.E., Martinez-Valdez H. Within germinal centers, isotype switching of immunoglobulin genes occurs after the onset of somatic mutation. Immunity 1996, 4:241-250.
51. Kurosaki T., Aiba Y., Kometani K., Moriyama S., Takahashi Y. Unique properties of memory B cells of different isotypes. Immunol. Rev. 2010, 237:104-116.
52. Macpherson A.J., Geuking M.B., McCoy K.D. Immunoglobulin A: a bridge between innate and adaptive immunity. Curr. Opin. Gastroenterol. 2011, 27:529-533.
53. Nimmerjahn F., Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005, 310:1510-1512.
54. Kalesnikoff J., Galli S.J. New developments in mast cell biology. Nat. Immunol. 2008, 9:1215-1223.
55. Talal N., Pillarisetty R.J., DeHoratius R.J., Messner R.P. Immunologic regulation of spontaneous antibodies to DNA and RNA I. Significance of IgM and IgG antibodies in SLE patients and asymptomatic relatives. Clin. Exp. Immunol. 1976, 25:377-382.
56. Rothfield N.F., Stollar B.D. The relation of immunoglobulin class, pattern of anti-nuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus. J. Clin. Invest. 1967, 46:1785-1794.
57. Pennebaker J.B., Gilliam J.N., Ziff M. Immunoglobulin classes of DNA binding activity in serum and skin in systemic lupus erythematosus. J. Clin. Invest. 1977, 60:1331-1338.
58. Hashimoto H., Utagawa Y., Yamagata J., Okada T., Shiokawa Y., Suzuki S., Tomiyama T. The relationship of renal histopathological lesions to immunoglobulin classes and complement fixation of anti-native DNA antibodies in systemic lupus erythematosus. Scand. J. Rheumatol. 1983, 12:209-214.
59. Yount W.J., Cohen P., Eisenberg R.A. Distribution of IgG subclasses among human autoantibodies to Sm, RNP, dsDNA, SS-B and IgG rheumatoid factor. Monogr. Allergy 1988, 23:41-56.
60. Elenitsas R., Abell E., Lee Y.Y., Huang J., Deng J.S. Comparison of IgG subclass autoantibodies in patients with systemic lupus erythematosus and subacute cutaneous lupus erythematosus. J. Dermatol. Sci. 1990, 1:207-215.
61. Wahren M., Ringertz N.R., Pettersson I. IgM and IgG subclass distribution of human anti-Ro/SSA 60 kDa autoantibodies. Scand. J. Immunol. 1994, 39:179-183.
62. Schur P.H., Monroe M., Rothfield N. The gammaG subclass of antinuclear and antinucleic acid antibodies. Arthritis Rheum. 1972, 15:174-182.
63. Verpoort K.N., Jol-van der Zijde C.M., Papendrecht-van der Voort E.A., Ioan-Facsinay A., Drijfhout J.W., van Tol M.J., Breedveld F.C., Huizinga T.W., Toes R.E. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum. 2006, 54:3799-3808.
64. van der Woude D., Syversen S.W., van der Voort E.I., Verpoort K.N., Goll G.L., van der Linden M.P., van der Helm-van Mil A.H., van der Heijde D.M., Huizinga T.W., Kvien T.K., Toes R.E. The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis. Ann. Rheum. Dis. 2010, 69:1110-1116.
65. Kokkonen H., Mullazehi M., Berglin E., Hallmans G., Wadell G., Ronnelid J., Rantapaa-Dahlqvist S. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res. Ther. 2011, 13:R13.
66. Syed R.H., Gilliam B.E., Moore T.L. Prevalence and significance of isotypes of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann. Rheum. Dis. 2008, 67:1049-1051.
67. Schuerwegh A.J., Ioan-Facsinay A., Dorjee A.L., Roos J., Bajema I.M., van der Voort E.I., Huizinga T.W., Toes R.E. Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:2586-2591.
68. Svard A., Kastbom A., Reckner-Olsson A., Skogh T. Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project. Arthritis Res. Ther. 2008, 10:R75.
69. Houssien D.A., Jonsson T., Davies E., Scott D.L. Rheumatoid factor isotypes, disease activity and the outcome of rheumatoid arthritis: comparative effects of different antigens. Scand. J. Rheumatol. 1998, 27:46-53.
70. Lindqvist E., Eberhardt K., Bendtzen K., Heinegard D., Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann. Rheum. Dis. 2005, 64:196-201.
71. Bobbio-Pallavicini F., Caporali R., Alpini C., Avalle S., Epis O.M., Klersy C., Montecucco C. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann. Rheum. Dis. 2007, 66:302-307.
72. Yanaba K., Bouaziz J.D., Matsushita T., Tsubata T., Tedder T.F. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J. Immunol. 2009, 182:7459-7472.
73. Evans J.G., Chavez-Rueda K.A., Eddaoudi A., Meyer-Bahlburg A., Rawlings D.J., Ehrenstein M.R., Mauri C. Novel suppressive function of transitional 2 B cells in experimental arthritis. J. Immunol. 2007, 178:7868-7878.
74. Lenert P., Brummel R., Field E.H., Ashman R.F. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J. Clin. Immunol. 2005, 25:29-40.
75. Fillatreau S., Sweenie C.H., McGeachy M.J., Gray D., Anderton S.M. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 2002, 3:944-950.
76. Mauri C., Gray D., Mushtaq N., Londei M. Prevention of arthritis by interleukin 10-producing B cells. J. Exp. Med. 2003, 197:489-501.
77. Yanaba K., Bouaziz J.D., Haas K.M., Poe J.C., Fujimoto M., Tedder T.F. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008, 28:639-650.
78. Blair P.A., Chavez-Rueda K.A., Evans J.G., Shlomchik M.J., Eddaoudi A., Isenberg D.A., Ehrenstein M.R., Mauri C. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J. Immunol. 2009, 182:3492-3502.
79. Gray M., Miles K., Salter D., Gray D., Savill J. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14080-14085.
80. Tian J., Zekzer D., Hanssen L., Lu Y., Olcott A., Kaufman D.L. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J. Immunol. 2001, 167:1081-1089.
81. Mann M.K., Maresz K., Shriver L.P., Tan Y., Dittel B.N. B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J. Immunol. 2007, 178:3447-3456.
82. Lundy S.K., Fox D.A. Reduced Fas ligand-expressing splenic CD5+ B lymphocytes in severe collagen-induced arthritis. Arthritis Res. Ther. 2009, 11:R128.
83. Bosma A., Abdel-Gadir A., Isenberg D.A., Jury E.C., Mauri C. Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells. Immunity 2012, 36:477-490.
84. Mizoguchi A., Mizoguchi E., Takedatsu H., Blumberg R.S., Bhan A.K. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002, 16:219-230.
85. Yanaba K., Yoshizaki A., Asano Y., Kadono T., Tedder T.F., Sato S. IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. Am. J. Pathol. 2011, 178:735-743.
86. Matsushita T., Yanaba K., Bouaziz J.D., Fujimoto M., Tedder T.F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 2008, 118:3420-3430.
87. Hussain S., Delovitch T.L. Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner. J. Immunol. 2007, 179:7225-7232.
88. Lundy S.K., Berlin A.A., Martens T.F., Lukacs N.W. Deficiency of regulatory B cells increases allergic airway inflammation. Inflamm. Res. 2005, 54:514-521.
89. Singh A., Carson W.F., Secor E.R., Guernsey L.A., Flavell R.A., Clark R.B., Thrall R.S., Schramm C.M. Regulatory role of B cells in a murine model of allergic airway disease. J. Immunol. 2008, 180:7318-7326.
90. Amu S., Saunders S.P., Kronenberg M., Mangan N.E., Atzberger A., Fallon P.G. Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. J. Allergy Clin. Immunol. 2010, 125:1114-1124.
91. Iwata Y., Matsushita T., Horikawa M., Dilillo D.J., Yanaba K., Venturi G.M., Szabolcs P.M., Bernstein S.H., Magro C.M., Williams A.D., Hall R.P., St Clair E.W., Tedder T.F. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011, 117:530-541.
92. Blair P.A., Norena L.Y., Flores-Borja F., Rawlings D.J., Isenberg D.A., Ehrenstein M.R., Mauri C. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010, 32:129-140.
93. Bouaziz J.D., Calbo S., Maho-Vaillant M., Saussine A., Bagot M., Bensussan A., Musette P. IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur. J. Immunol. 2010, 40:2686-2691.
94. Correale J., Farez M., Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann. Neurol. 2008, 64:187-199.
95. Knippenberg S., Peelen E., Smolders J., Thewissen M., Menheere P., Cohen Tervaert J.W., Hupperts R., Damoiseaux J. Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naive/memory Breg ratio during a relapse but not in remission. J. Neuroimmunol. 2011, 239:80-86.
96. Roussey-Kesler G., Giral M., Moreau A., Subra J.F., Legendre C., Noel C., Pillebout E., Brouard S., Soulillou J.P. Clinical operational tolerance after kidney transplantation. Am. J. Transplant. 2006, 6:736-746.
97. Jeannet M., Pinn V.W., Flax M.H., Winn H.J., Russell P.S. Humoral antibodies in renal allotransplantation in man. N. Engl. J. Med. 1970, 282:111-117.
98. Thaunat O., Louedec L., Dai J., Bellier F., Groyer E., Delignat S., Gaston A.T., Caligiuri G., Joly E., Plissonnier D., Michel J.B., Nicoletti A. Direct and indirect effects of alloantibodies link neointimal and medial remodeling in graft arteriosclerosis. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2359-2365.
99. Russell P.S., Chase C.M., Colvin R.B. Alloantibody- and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis: lack of progression to sclerotic lesions in B cell-deficient mice. Transplantation 1997, 64:1531-1536.
100. Terasaki P.I., Ozawa M., Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am. J. Transplant. 2007, 7:408-415.
101. Terasaki P.I., Cai J. Humoral theory of transplantation: further evidence. Curr. Opin. Immunol. 2005, 17:541-545.
102. Issa N., Cosio F.G., Gloor J.M., Sethi S., Dean P.G., Moore S.B., DeGoey S., Stegall M.D. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008, 86:681-685.
103. Einecke G., Sis B., Reeve J., Mengel M., Campbell P.M., Hidalgo L.G., Kaplan B., Halloran P.F. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am. J. Transplant. 2009, 9:2520-2531.
104. Sumitran-Karuppan S., Tyden G., Reinholt F., Berg U., Moller E. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transpl. Immunol. 1997, 5:321-327.
105. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005, 365:1570-1576.
106. Amico P., Honger G., Bielmann D., Lutz D., Garzoni D., Steiger J., Mihatsch M.J., Dragun D., Schaub S. Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen-antibodies. Transplantation 2008, 85:1557-1563.
107. Ismail A.M., Badawi R.M., El-Agroudy A.E., Mansour M.A. Pretransplant detection of anti-endothelial cell antibodies could predict renal allograft outcome. Exp. Clin. Transplant. 2009, 7:104-109.
108. Lucchiari N., Panajotopoulos N., Xu C., Rodrigues H., Ianhez L.E., Kalil J., Glotz D. Antibodies eluted from acutely rejected renal allografts bind to and activate human endothelial cells. Hum. Immunol. 2000, 61:518-527.
109. Le Bas-Bernardet S., Hourmant M., Coupel S., Bignon J.D., Soulillou J.P., Charreau B. Non-HLA-type endothelial cell reactive alloantibodies in pre-transplant sera of kidney recipients trigger apoptosis. Am. J. Transplant. 2003, 3:167-177.
110. Bordron A., Revelen R., D'Arbonneau F., Dueymes M., Renaudineau Y., Jamin C., Youinou P. Functional heterogeneity of anti-endothelial cell antibodies. Clin. Exp. Immunol. 2001, 124:492-501.
111. Hankey K.G., Drachenberg C.B., Papadimitriou J.C., Klassen D.K., Philosophe B., Bartlett S.T., Groh V., Spies T., Mann D.L. MIC expression in renal and pancreatic allografts. Transplantation 2002, 73:304-306.
112. Quiroga I., Salio M., Koo D.D., Cerundolo L., Shepherd D., Cerundolo V., Fuggle S.V. Expression of MHC class I-related Chain B (MICB) molecules on renal transplant biopsies. Transplantation 2006, 81:1196-1203.
113. Mizutani K., Terasaki P., Rosen A., Esquenazi V., Miller J., Shih R.N., Pei R., Ozawa M., Lee J. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am. J. Transplant. 2005, 5:2265-2272.
114. Suarez-Alvarez B., Lopez-Vazquez A., Gonzalez M.Z., Fdez-Morera J.L., Diaz-Molina B., Blanco-Gelaz M.A., Pascual D., Martinez-Borra J., Muro M., Alvarez-Lopez M.R., Lopez-Larrea C. The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection. Am. J. Transplant. 2007, 7:1842-1848.
115. Zou Y., Mirbaha F., Lazaro A., Zhang Y., Lavingia B., Stastny P. MICA is a target for complement-dependent cytotoxicity with mouse monoclonal antibodies and human alloantibodies. Hum. Immunol. 2002, 63:30-39.
116. Alvarez-Marquez A., Aguilera I., Gentil M.A., Caro J.L., Bernal G., Fernandez A.J., Acevedo M.J., Cabello V., Wichmann I., Gonzalez-Escribano M.F., Nunez-Roldan A. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies. Transplantation 2009, 87:94-99.
117. Fukami N., Ramachandran S., Saini D., Walter M., Chapman W., Patterson G.A., Mohanakumar T. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J. Immunol. 2009, 182:309-318.
118. Mahesh B., Leong H.S., McCormack A., Sarathchandra P., Holder A., Rose M.L. Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am. J. Pathol. 2007, 170:1415-1427.
119. Jurcevic S., Ainsworth M.E., Pomerance A., Smith J.D., Robinson D.R., Dunn M.J., Yacoub M.H., Rose M.L. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001, 71:886-892.
120. Barber L.D., Whitelegg A., Madrigal J.A., Banner N.R., Rose M.L. Detection of vimentin-specific autoreactive CD8+ T cells in cardiac transplant patients. Transplantation 2004, 77:1604-1609.
121. Iwata T., Philipovskiy A., Fisher A.J., Presson R.G., Chiyo M., Lee J., Mickler E., Smith G.N., Petrache I., Brand D.B., Burlingham W.J., Gopalakrishnan B., Greenspan D.S., Christie J.D., Wilkes D.S. Anti-type V collagen humoral immunity in lung transplant primary graft dysfunction. J. Immunol. 2008, 181:5738-5747.
122. Burlingham W.J., Love R.B., Jankowska-Gan E., Haynes L.D., Xu Q., Bobadilla J.L., Meyer K.C., Hayney M.S., Braun R.K., Greenspan D.S., Gopalakrishnan B., Cai J., Brand D.D., Yoshida S., Cummings O.W., Wilkes D.S. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J. Clin. Invest. 2007, 117:3498-3506.
123. Joosten S.A., Sijpkens Y.W., van H.V., Trouw L.A., d.van V., van den Heuvel B., van K.C., Paul L.C. Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am. J. Transplant. 2005, 5:383-393.
124. Dragun D., Muller D.N., Brasen J.H., Fritsche L., Nieminen-Kelha M., Dechend R., Kintscher U., Rudolph B., Hoebeke J., Eckert D., Mazak I., Plehm R., Schonemann C., Unger T., Budde K., Neumayer H.H., Luft F.C., Wallukat G. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N. Engl. J. Med. 2005, 352:558-569.
125. Thaunat O., Graff-Dubois S., Fabien N., Duthey A., Attuil-Audenis V., Nicoletti A., Patey N., Morelon E. A stepwise breakdown of B-cell tolerance occurs within renal allografts during chronic rejection. Kidney Int. 2012, 81:207-219.
126. Valujskikh A., Lantz O., Celli S., Matzinger P., Heeger P.S. Cross-primed CD8(+) T cells mediate graft rejection via a distinct effector pathway. Nat. Immunol. 2002, 3:844-851.
127. Baddoura F.K., Nasr I.W., Wrobel B., Li Q., Ruddle N.H., Lakkis F.G. Lymphoid neogenesis in murine cardiac allografts undergoing chronic rejection. Am. J. Transplant. 2005, 5:510-516.
128. Segerer S., Bohmig G.A., Exner M., Kerjaschki D., Regele H., Schlondorff D. Role of CXCR3 in cellular but not humoral renal allograft rejection. Transpl. Int. 2005, 18:676-680.
129. Thaunat O. Humoral immunity in chronic allograft rejection: puzzle pieces come together. Transpl. Immunol. 2012, 26:101-106.
130. Newell K.A., Asare A., Kirk A.D., Gisler T.D., Bourcier K., Suthanthiran M., Burlingham W.J., Marks W.H., Sanz I., Lechler R.I., Hernandez-Fuentes M.P., Turka L.A., Seyfert-Margolis V.L. Identification of a B cell signature associated with renal transplant tolerance in humans. J. Clin. Invest. 2010, 120:1836-1847.
131. Braza F., Soulillou J.P., Brouard S. Gene expression signature in transplantation tolerance. Clin. Chim. Acta 2012, 413:1414-1418.
132. Pallier A., Hillion S., Danger R., Giral M., Racape M., Degauque N., Dugast E., Ashton-Chess J., Pettre S., Lozano J.J., Bataille R., Devys A., Cesbron-Gautier A., Braudeau C., Larrose C., Soulillou J.P., Brouard S. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int. 2010, 78:503-513.
133. Sagoo P., Perucha E., Sawitzki B., Tomiuk S., Stephens D.A., Miqueu P., Chapman S., Craciun L., Sergeant R., Brouard S., Rovis F., Jimenez E., Ballow A., Giral M., Rebollo-Mesa I., Le M.A., Braudeau C., Hilton R., Gerstmayer B., Bourcier K., Sharif A., Krajewska M., Lord G.M., Roberts I., Goldman M., Wood K.J., Newell K., Seyfert-Margolis V., Warrens A.N., Janssen U., Volk H.D., Soulillou J.P., Hernandez-Fuentes M.P., Lechler R.I. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J. Clin. Invest. 2010, 120:1848-1861.
134. Brouard S., Mansfield E., Braud C., Li L., Giral M., Hsieh S.C., Baeten D., Zhang M., Ashton-Chess J., Braudeau C., Hsieh F., Dupont A., Pallier A., Moreau A., Louis S., Ruiz C., Salvatierra O., Soulillou J.P., Sarwal M. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15448-15453.
135. Le T.L., Thebault P., Lavault A., Usal C., Merieau E., Quillard T., Charreau B., Soulillou J.P., Cuturi M.C., Brouard S., Chiffoleau E. Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile. Am. J. Transplant. 2011, 11:429-438.
136. Louis S., Braudeau C., Giral M., Dupont A., Moizant F., Robillard N., Moreau A., Soulillou J.P., Brouard S. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006, 81:398-407.
137. Heidt S., Hester J., Shankar S., Friend P.J., Wood K.J. B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naive B cells. Am. J. Transplant. 2012, 12:1784-1792.
138. Knechtle S.J., Pascual J., Bloom D.D., Torrealba J.R., Jankowska-Gan E., Burlingham W.J., Kwun J., Colvin R.B., Seyfert-Margolis V., Bourcier K., Sollinger H.W. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am. J. Transplant. 2009, 9:1087-1098.
139. Lassila O., Vainio O., Matzinger P. Can B cells turn on virgin T cells?. Nature 1988, 334:253-255.
140. Fuchs E.J., Matzinger P. B cells turn off virgin but not memory T cells. Science 1992, 258:1156-1159.
141. Eynon E.E., Parker D.C. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J. Exp. Med. 1992, 175:131-138.
142. Reichardt P., Dornbach B., Rong S., Beissert S., Gueler F., Loser K., Gunzer M. Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood 2007, 110:1519-1529.
143. Morlacchi S., Soldani C., Viola A., Sarukhan A. Self-antigen presentation by mouse B cells results in regulatory T-cell induction rather than anergy or clonal deletion. Blood 2011, 118:984-991.
144. Chen X., Jensen P.E. Cutting edge: primary B lymphocytes preferentially expand allogeneic FoxP3+ CD4 T cells. J. Immunol. 2007, 179:2046-2050.
145. Billingham R.E., Brent L., Medawar P.B. Actively acquired tolerance of foreign cells. Nature 1953, 172:603-606.
146. Fan X., Ang A., Pollock-Barziv S.M., Dipchand A.I., Ruiz P., Wilson G., Platt J.L., West L.J. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat. Med. 2004, 10:1227-1233.
147. Parsons R.F., Vivek K., Redfield R.R., Migone T.S., Cancro M.P., Naji A., Noorchashm H. B-cell tolerance in transplantation: is repertoire remodeling the answer?. Expert Rev. Clin. Immunol. 2009, 5:703.
148. Parsons R.F., Vivek K., Rostami S.Y., Zekavat G., Ziaie S.M., Luo Y., Koeberlein B., Redfield R.R., Cancro M.P., Naji A., Noorchashm H. Acquisition of humoral transplantation tolerance upon de novo emergence of B lymphocytes. J. Immunol. 2011, 186:614-620.
149. Cancro M.P. Signalling crosstalk in B cells: managing worth and need. Nat. Rev. Immunol. 2009, 9:657-661.
150. Mauri C., Blair P.A. Regulatory B cells in autoimmunity: developments and controversies. Nat. Rev. Rheumatol. 2010, 6:636-643.
151. Boumpas D.T., Furie R., Manzi S., Illei G.G., Wallace D.J., Balow J.E., Vaishnaw A. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003, 48:719-727.
152. Landewe R.B., Houbiers J.G., Van den Bosch F., in't H.J., Verschueren P.C., Meijerink J.H., van den Hoogen F.H., Masek B.A., Bruyn G.A., Wouters J.M., Voskuyl A.E., van Laar J.M., Bijlsma J.J., van der Heijde D.M., Breedveld F.C., van de Putte L.B., Miltenburg A.M., De K.F. Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial. Ann. Rheum. Dis. 2010, 69:1655-1659.
153. Weiner H.L., Mackin G.A., Matsui M., Orav E.J., Khoury S.J., Dawson D.M., Hafler D.A. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993, 259:1321-1324.
154. Cantaert T., Brouard S., Thurlings R.M., Pallier A., Salinas G.F., Braud C., Klarenbeek P.L., de V.N., Zhang Y., Soulillou J.P., Tak P.P., Baeten D. Alterations of the synovial T cell repertoire in anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheum. 2009, 60:1944-1956.
155. Klarenbeek P.L., de Hair M.J., Doorenspleet M.E., van Schaik B.D., Esveldt R.E., van de Sande M.G., Cantaert T., Gerlag D.M., Baeten D., van Kampen A.H., Baas F., Tak P.P., de V.N. Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease. Ann. Rheum. Dis. 2012, 71:1088-1093.
156. Sun J.B., Czerkinsky C., Holmgren J. B lymphocytes treated in vitro with antigen coupled to cholera toxin B subunit induce antigen-specific Foxp3(+) regulatory T cells and protect against experimental autoimmune encephalomyelitis. J. Immunol. 2012, 188:1686-1697.
157. Ramgolam V.S., Sha Y., Marcus K.L., Choudhary N., Troiani L., Chopra M., Markovic-Plese S. B cells as a therapeutic target for IFN-beta in relapsing-remitting multiple sclerosis. J. Immunol. 2011, 186:4518-4526.